Physician profile
Asha Sd Nuthi
NPI 1851393243
$2,161.34
in general payments reported to CMS, 2019-2025
18 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $55.92 · 2021: $243 · 2022: $237 · 2023: $262 · 2024: $438 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286 · Entertainment: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.86 |
| Entertainment | $233.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $364.20 | 2023-2025 | Izervay |
| Alcon Vision LLC | $350.51 | 2019-2025 | Clareon Panoptix Pro, Hydrus Microstent |
| Harrow Eye, LLC | $298.86 | 2025 | Iheezo, Vevye, Triesence |
| Optos, INC. | $233.76 | 2023-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Genentech USA, INC. | $203.06 | 2022-2025 | Vabysmo |
| Biotissue Holdings INC. | $139.06 | 2024 | |
| Horizon Therapeutics Plc | $109.91 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $92.86 | 2021-2025 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $86.70 | 2019-2023 | |
| Abbvie INC. | $54.57 | 2023-2025 | |
| Oyster Point Pharma, INC. | $37.55 | 2022 | |
| Sun Pharmaceutical Industries INC. | $37.45 | 2021 | |
| Maculogix, INC. | $33.97 | 2020 | |
| Apellis Pharmaceuticals, INC. | $32.14 | 2024 | Syfovre |
| Kala Pharmaceuticals, INC. | $24.44 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $24.18 | 2019 | |
| Allergan, INC. | $21.28 | 2021 | |
| Bausch & Lomb Americas INC. | $16.84 | 2024 | Miebo, Vyzulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Nuthi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.